CUR - Neuralstem, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.10
+0.02 (+1.85%)
At close: 1:00PM EST
Stock chart is not supported by your current browser
Previous Close1.08
Open1.09
Bid1.09 x 400
Ask1.16 x 900
Day's Range1.05 - 1.11
52 Week Range0.23 - 6.60
Volume75,578
Avg. Volume547,493
Market Cap16.661M
Beta0.75
PE Ratio (TTM)N/A
EPS (TTM)-2.22
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.00
Trade prices are not sourced from all markets
  • GlobeNewswire8 days ago

    Neuralstem Announces Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at the Upcoming American College of Neuropsychopharmacology Annual Meeting

    GERMANTOWN, Md., Nov. 16, 2017-- Neuralstem, Inc., a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that data from the Company’ s Phase 2 study of NSI-189 ...

  • Associated Press11 days ago

    Neuralstem reports 3Q loss

    On a per-share basis, the Germantown, Maryland-based company said it had a loss of 18 cents. The biopharmaceutical company posted revenue of $2,500 in the period. Its adjusted revenue was $3,000. The company's ...

  • GlobeNewswire11 days ago

    Neuralstem Reports Third Quarter 2017 Fiscal Results and Provides Clinical and Business Update

    GERMANTOWN, Md., Nov. 13, 2017-- Neuralstem, Inc., a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, reported its financial results ...

  • Capital Cube14 days ago

    ETFs with exposure to Neuralstem, Inc. : November 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Neuralstem, Inc. :CUR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
    Capital Cube15 days ago

    Neuralstem, Inc. :CUR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017

    Categories: Yahoo FinanceGet free summary analysis Neuralstem, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Neuralstem, Inc. – Cytokinetics, Incorporated, Geron Corporation, Acorda Therapeutics, Inc., Aceto Corporation, Intra-Cellular Therapies, Inc., Supernus Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc. (CYTK-US, GERN-US, ACOR-US, ACET-US, ITCI-US, SUPN-US and ... Read more (Read more...)

  • GlobeNewswire16 days ago

    Neuralstem Strengthens Executive Leadership Team with Appointment of Dr. David Recker as Chief Medical Officer

    GERMANTOWN, Md., Nov. 08, 2017-- Neuralstem, Inc., a biopharmaceutical company developing novel treatments for nervous system diseases, today announced the appointment of David Recker, MD, FACR, FACP, ...

  • One Thing To Consider Before Buying Neuralstem Inc (CUR)
    Simply Wall St.last month

    One Thing To Consider Before Buying Neuralstem Inc (CUR)

    For Neuralstem Inc’s (NASDAQ:CUR) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. Every stock in theRead More...

  • ACCESSWIRE2 months ago

    Neuralstem: Stock falls in July on Phase II Miss, Gets 2 New Patents for Neural Stem Cells

    NEW YORK, NY / ACCESSWIRE / September 27, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • GlobeNewswire2 months ago

    Neuralstem Announces the Appointment of Two New Members to the Board of Directors

    GERMANTOWN, Md., Sept. 25, 2017-- Neuralstem, Inc., a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that Zhang Zhuo and Cristina Csimma, PharmD, MHP, ...

  • Capital Cube2 months ago

    ETFs with exposure to Neuralstem, Inc. : September 22, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube2 months ago

    ETFs with exposure to Neuralstem, Inc. : September 12, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • TheStreet.com3 months ago

    Intra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers

    Standard treatments can cause motor side effects and/or weight gain, cardiovascular complications, dyslipidemia, and hyperglycemia.

  • GlobeNewswire3 months ago

    Neuralstem Announces Issuance of Two U.S. Patents

    GERMANTOWN, Md., Sept. 07, 2017-- Neuralstem, Inc., a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that it has been awarded two additional patents ...

  • Capital Cube3 months ago

    ETFs with exposure to Neuralstem, Inc. : August 31, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Neuralstem, Inc. :CUR-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
    Capital Cube3 months ago

    Neuralstem, Inc. :CUR-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017

    Categories: Yahoo FinanceGet free summary analysis Neuralstem, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Neuralstem, Inc. – Titan Pharmaceuticals, Inc., Cytokinetics, Incorporated, Acorda Therapeutics, Inc., Geron Corporation, Neurocrine Biosciences, Inc., Albany Molecular Research, Inc., BioTime, Inc., Charles River Laboratories International, Inc. and Repligen ... Read more (Read more...)

  • Associated Press4 months ago

    Neuralstem reports 2Q loss

    The Germantown, Maryland-based company said it had a loss of 39 cents per share. The biopharmaceutical company posted revenue of $2,500 in the period. Its adjusted revenue was $3,000. The company's shares ...

  • Accesswire4 months ago

    Today's Research Reports on Stocks to Watch: Neuralstem and Flex Pharma

    NEW YORK, NY / ACCESSWIRE / July 26, 2017 / Neuralstem was a big loser in Tuesday trading, dropping as much as 61% in pre-market trading before bouncing back slightly. The company missed its primary endpoint ...

  • Capital Cube5 months ago

    ETFs with exposure to Neuralstem, Inc. : July 4, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)